0001564590-20-021925.txt : 20200506 0001564590-20-021925.hdr.sgml : 20200506 20200506160927 ACCESSION NUMBER: 0001564590-20-021925 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20200506 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENANTA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001177648 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35839 FILM NUMBER: 20852677 BUSINESS ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617 607 0800 MAIL ADDRESS: STREET 1: 500 ARSENAL STREET CITY: WATERTOWN STATE: MA ZIP: 02472 8-K 1 enta-8k_20200506.htm 8-K Q2 2020 EARNINGS RELEASE enta-8k_20200506.htm
false 0001177648 0001177648 2020-05-06 2020-05-06

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2020

 

ENANTA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-35839

04-3205099

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

 

 

 

500 Arsenal Street,

Watertown, Massachusetts

 

02472

(Address of principal executive offices, including zip code)

Registrant’s Telephone Number, Including Area Code: (617) 607-0800

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock

 

ENTA

 

NASDAQ

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On May 6, 2020, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended March 31, 2020. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

 

Description

99.1

 

Press Release of Enanta Pharmaceuticals, Inc. dated May 6, 2020, reporting Enanta’s financial results for the fiscal quarter ended March 31, 2020.

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

ENANTA PHARMACEUTICALS, INC.

 

 

 

 

Date: May 6, 2020

 

By:

/s/ Paul J. Mellett

 

 

 

Paul J. Mellett

 

 

 

Senior Vice President, Finance and Administration and Chief Financial Officer

 

2

 EX-99.1 2 enta-ex991_6.htm EX-99.1 enta-ex991_6.htm

Exhibit 99.1

 

For Immediate Release

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET

 

•

On Track to Initiate Phase 1b Study of EDP-514 in Viremic Hepatitis B Patients in 2Q 2020 and Phase 1 Study of EDP-297 in 3Q 2020  

 

•

Royalty Revenue for the Quarter was $27.6 Million

 

•

Cash and Marketable Securities Totaled $435.4 Million at March 31, 2020

WATERTOWN, Mass., May 6, 2020 – Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2020.

“Enanta is fortunate to have advanced several of its programs in the recent quarter and it continues to have a strong balance sheet and ongoing royalty funding to support its business plans going forward,” said Jay R. Luly, President and Chief Executive Officer of Enanta Pharmaceuticals. “The current pandemic has underscored our commitment as a company to bring forth novel anti-viral therapies for respiratory viruses and liver infections, and we remain highly dedicated to the clinical advancement of our innovative small molecule pipeline. We are on schedule to initiate our Phase 1b study of EDP-514 in viremic hepatitis B patients this quarter, and we also expect to initiate a first-in-human study of our follow-on Farnesoid X receptor agonist, EDP-297, next quarter. Additionally, we have plans for two additional studies of EDP-938 for respiratory syncytial virus to start by year-end, one in pediatric patients and one in adult transplant patients. With these catalysts in mind, we continue to monitor any impact of COVID-19 on all of our clinical studies.”

Fiscal Second Quarter Ended March 31, 2020 Financial Results

Total revenue for the three months ended March 31, 2020 was $27.6 million and consisted of royalty revenue derived primarily from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir). For the three months ended March 31, 2019, total revenue was $39.6 million, which consisted of royalty revenue earned on AbbVie’s global net sales of its HCV regimens. AbbVie has reported that the decrease in its first quarter 2020 HCV sales was due to lower patient volumes in select international markets where patients are treated in hospitals affected by COVID-19, as well as increased competition affecting pricing and market share within the U.S. Managed Medicaid segment.

Research and development expenses totaled $32.6 million for the three months ended March 31, 2020, compared to $34.2 million for the three months ended March 31, 2019. The decrease in research and development expenses was primarily due to a decrease in clinical trial expense due to timing of Phase 2

Enanta Pharmaceuticals, Inc. Page | 1 of 7

 

studies in non-alcoholic steatohepatitis (NASH)/primary biliary cholangitis (PBC) conducted in the prior year.

General and administrative expenses totaled $6.9 million for the three months ended March 31, 2020, compared to $6.8 million for the three months ended March 31, 2019.

Enanta recorded an income tax benefit of $3.9 million for the three months ended March 31, 2020 compared to an income tax benefit of $3.2 million for the same period of 2019. The income tax benefit for the three months ended March 31, 2020 was due to a pre-tax loss and increased research and development tax credits. In the prior year, Enanta recorded an income tax benefit despite reporting pre-tax income due to tax deductions from employee stock award-related activity during the quarter.

Net loss for the three months ended March 31, 2020 was $6.0 million, or a loss of $0.30 per diluted common share, compared to net income of $4.1 million, or $0.20 per diluted common share, for the corresponding period in 2019.

Enanta’s cash, cash equivalents and short-term and long-term marketable securities totaled $435.4 million at March 31, 2020. This compares to a total of $400.3 million at September 30, 2019. Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs for the foreseeable future.

Pipeline Programs and Near-term Milestones

 

•

Respiratory Syncytial Virus (RSV): N-Protein Inhibitor EDP-938, Human Metapneumovirus (hMPV) and SARS-CoV-2

 

­

Continue with plans to broaden the RSVP study into the Southern Hemisphere, and to expand to trials sites in Europe and North America in the fall and winter RSV season, with the goal of having data in the third quarter of 2021

 

­

Plan to initiate Phase 2 dose ranging study in pediatric patients with RSV in 4Q 2020

 

­

Plan to initiate Phase 2 study in adult transplant patients with RSV in 4Q 2020

 

­

Perform optimization of Enanta’s current nanomolar hMPV inhibitor leads

 

­

Advance efforts for discovery of direct-acting antiviral compounds for SARS-CoV-2

 

 

•

Hepatitis B (HBV): Core Inhibitor EDP-514

 

­

Initiate Phase 1b study in viremic HBV patients in 2Q 2020

 

­

Resume recruitment in Phase 1b study in nuc-suppressed HBV patients, currently paused

 

 

•

Non-Alcoholic Steatohepatitis (NASH): Farnesoid X Receptor (FXR) Agonists EDP-305 and EDP-297

 

­

Resume recruitment and dosing in ARGON-2 Phase 2b study of EDP-305 in NASH, currently paused

 

­

Plan to initiate Phase 1 study of EDP-297 (follow-on FXR for NASH) in 3Q 2020

 

­

Advance efforts for discovery of non-FXR compounds for NASH

 

 

•

Hepatitis C (HCV) Collaboration with AbbVie

Enanta Pharmaceuticals, Inc. Page | 2 of 7

 

 

­

AbbVie announced that the European Commission approved a change to the marketing authorization for MAVIRET® (glecaprevir/pibrentasvir) to shorten once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic HCV patients with genotype (GT) 3 infection. The decision makes MAVIRET the only pan-genotypic (GTs 1-6) 8-week treatment option for treatment-naïve, chronic HCV patients, without cirrhosis or with compensated cirrhosis.

 

Upcoming Events and Presentations

 

•

May 19, 2020 – RBC Capital Markets Global Healthcare Conference, Virtual

 

•

June 18, 2020 – Raymond James Healthcare Conference, Virtual

 

•

Enanta plans to issue its fiscal third quarter financial results press release, and hold a conference call regarding those results, on August 4, 2020.

 

Conference Call and Webcast Information

Enanta will host a conference call and webcast today at 4:30 p.m. ET. To participate in the live conference call, please dial (855) 840-0595 in the U.S. or (518) 444-4814 for international callers.  A replay of the conference call will be available starting at approximately 7:30 p.m. ET on May 6, 2020, through 11:59 p.m. ET on May 8, 2020 by dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international callers. The passcode for both the live call and the replay is 4261269. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentation” section on the “Investors” page of Enanta’s website at www.enanta.com.

 

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV) and emerging coronaviruses, including SARS-CoV-2.

 

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta and now marketed by AbbVie as part of its leading treatment for chronic HCV infection, is sold under the brand names MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

 

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enanta’s clinical programs in RSV, NASH and HBV, as well as discovery programs in hMPV and SARS-CoV-2, and prospects for future royalty revenue from sales of AbbVie’s MAVYRET®/MAVIRET® HCV regimen. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this

Enanta Pharmaceuticals, Inc. Page | 3 of 7

 

release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta’s revenues in the short-term are dependent upon the level of AbbVie’s sales of its MAVYRET®/MAVIRET® HCV regimen; the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for RSV, NASH, and HBV; competitive pricing, market acceptance and reimbursement rate actions affecting MAVYRET®/MAVIRET® compared to competitive HCV products on the market; the discovery and development risks of Enanta’s programs in RSV, NASH, HBV, hMPV, SARS-CoV-2; the competitive impact of development, regulatory and marketing efforts of others in those disease areas; Enanta’s lack of clinical development experience; Enanta’s need to attract and retain senior management and key research and development personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Form 10-Q for the quarter ended December 31, 2019, and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.

 

Media and Investor Contact:
Jennifer Viera

617-744-3848

jviera@enanta.com

 

 

###

 


Enanta Pharmaceuticals, Inc. Page | 4 of 7

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

ENANTA PHARMACEUTICALS, INC.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

UNAUDITED

(in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

 

 

 

March 31,

 

 

March 31,

 

 

 

 

 

 

2020

 

 

2019

 

 

2020

 

 

2019

 

Revenue

$

27,619

 

 

$

39,631

 

 

$

80,189

 

 

$

109,517

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

32,610

 

 

 

34,155

 

 

 

65,388

 

 

 

69,033

 

 

General and administrative

 

6,884

 

 

 

6,780

 

 

 

13,805

 

 

 

13,932

 

 

 

Total operating expenses

 

39,494

 

 

 

40,935

 

 

 

79,193

 

 

 

82,965

 

Income (loss) from operations

 

(11,875

)

 

 

(1,304

)

 

 

996

 

 

 

26,552

 

Other income, net

 

1,950

 

 

 

2,245

 

 

 

4,026

 

 

 

4,130

 

Income (loss) before income taxes

 

(9,925

)

 

 

941

 

 

 

5,022

 

 

 

30,682

 

Income tax (expense) benefit

 

3,920

 

 

 

3,204

 

 

 

2,416

 

 

 

(526

)

Net income (loss)

$

(6,005

)

 

$

4,145

 

 

$

7,438

 

 

$

30,156

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

$

(0.30

)

 

$

0.21

 

 

$

0.37

 

 

$

1.55

 

 

Diluted

 

 

$

(0.30

)

 

$

0.20

 

 

$

0.36

 

 

$

1.44

 

Weighted average common shares outstanding

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

 

19,922

 

 

 

19,549

 

 

 

19,836

 

 

 

19,487

 

 

Diluted

 

 

 

19,922

 

 

 

21,084

 

 

 

20,692

 

 

 

20,946

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Enanta Pharmaceuticals, Inc. Page | 5 of 7

 

ENANTA PHARMACEUTICALS, INC.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

UNAUDITED

(in thousands)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31,

 

 

September 30,

 

 

 

 

 

2020

 

 

2019

 

Assets

 

 

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

$

74,338

 

 

$

51,230

 

 

Short-term marketable securities

 

280,917

 

 

 

284,006

 

 

Accounts receivable

 

27,619

 

 

 

51,313

 

 

Prepaid expenses and other current assets

 

19,835

 

 

 

15,299

 

 

 

Total current assets

 

402,709

 

 

 

401,848

 

Long-term marketable securities

 

 

80,099

 

 

 

65,013

 

Property and equipment, net

 

 

9,738

 

 

 

10,927

 

Deferred tax assets

 

 

12,418

 

 

 

11,341

 

Operating lease, right-of-use assets

 

 

7,837

 

 

 

-

 

Restricted cash

 

 

608

 

 

 

608

 

Other long-term assets

 

 

92

 

 

 

92

 

 

 

Total assets

$

513,501

 

 

$

489,829

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

 

Accounts payable

$

5,945

 

 

$

6,689

 

 

Accrued expenses and other current liabilities

 

9,807

 

 

 

15,920

 

 

Operating lease liabilities

 

3,764

 

 

 

-

 

 

 

Total current liabilities

 

19,516

 

 

 

22,609

 

Operating lease liabilities, net of current portion

 

 

5,330

 

 

 

-

 

Series 1 nonconvertible preferred stock

 

 

1,628

 

 

 

1,628

 

Other long-term liabilities

 

 

1,036

 

 

 

3,100

 

 

 

Total liabilities

 

27,510

 

 

 

27,337

 

Total stockholders' equity

 

 

485,991

 

 

 

462,492

 

 

 

Total liabilities and stockholders' equity

$

513,501

 

 

$

489,829

 

 

 

 

Enanta Pharmaceuticals, Inc. Page | 6 of 7

 

 GRAPHIC 3 ga53z3s3edsx000001.jpg GRAPHIC begin 644 ga53z3s3edsx000001.jpg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end EX-101.SCH 4 enta-20200506.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 enta-20200506_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Entity Registrant Name Entity Registrant Name Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Document Period End Date Document Period End Date Entity Emerging Growth Company Entity Emerging Growth Company Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre Commencement Tender Offer Pre-commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 6 enta-20200506_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports enta-8k_20200506.htm enta-20200506.xsd enta-20200506_lab.xml enta-20200506_pre.xml enta-ex991_6.htm http://xbrl.sec.gov/dei/2019-01-31 true false XML 8 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end JSON 10 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "enta-8k_20200506.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "enta-8k_20200506.htm" ] }, "labelLink": { "local": [ "enta-20200506_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "enta-20200506_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "enta-20200506.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "enta", "nsuri": "http://www.enanta.com/20200506", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "enta-8k_20200506.htm", "contextRef": "C_0001177648_20200506_20200506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "enta-8k_20200506.htm", "contextRef": "C_0001177648_20200506_20200506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.enanta.com/20200506/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} ZIP 12 0001564590-20-021925-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-20-021925-xbrl.zip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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
May 06, 2020
Cover [Abstract]  
Entity Registrant Name ENANTA PHARMACEUTICALS, INC.
Document Type 8-K
Amendment Flag false
Entity Central Index Key 0001177648
Document Period End Date May 06, 2020
Entity Emerging Growth Company false
Entity File Number 001-35839
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 04-3205099
Entity Address, Address Line One 500 Arsenal Street
Entity Address, City or Town Watertown
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02472
City Area Code (617)
Local Phone Number 607-0800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol ENTA
Security Exchange Name NASDAQ

XML 14 enta-8k_20200506_htm.xml IDEA: XBRL DOCUMENT 0001177648 2020-05-06 2020-05-06 false 0001177648 8-K 2020-05-06 ENANTA PHARMACEUTICALS, INC. DE 001-35839 04-3205099 500 Arsenal Street Watertown MA 02472 (617) 607-0800 false false false false Common Stock ENTA NASDAQ false